REQUIP XL
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
REQUIP XL by GSK is non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the d 2 and d 3 dopamine receptor subtypes, binding with higher affinity to d 3 than to d 2 or d 4 receptor subtypes. Approved for signs, symptoms of idiopathic parkinson’s disease, the signs. First approved in 2008.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REQUIP XL (ropinirole) is an extended-release, non-ergoline dopamine agonist oral tablet approved for treating signs and symptoms of idiopathic Parkinson's disease. It works by stimulating postsynaptic dopamine D2-type receptors in the brain, particularly in the caudate-putamen region, to restore motor function. The drug has higher affinity for D3 receptors than D2 or D4 subtypes, though the clinical relevance of D3 binding in Parkinson's disease remains unknown.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting team and shift toward lifecycle management and retention strategies.
Mechanism of Action
non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D 2 and D 3 dopamine receptor subtypes, binding with higher affinity to D 3 than to D 2 or D 4 receptor subtypes. Ropinirole has moderate in vitro affinity for opioid receptors. Ropinirole and…
Indications (3)
Worked on REQUIP XL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.